Business & Investment

COVID-19 vaccine to replace AstraZeneca in the UK under 40: Report

AstraZeneca alternatives are offered to people under the age of 40 in the UK
AZN,
-0.32%

AZN,
+ 0.10%

The COVID-19 vaccine as a precautionary measure was reported on Thursday by several media outlets, following concerns about rare blood clots associated with shots.

The Joint Committee on Immunization and Immunization (JCVI), a committee of experts to advise the government, will provide healthy people between the ages of 30 and 39 with a vaccine co-developed by BioTech BioNTech on Friday. I will recommend that.
BNTX,
-1.62%

Pharmaceutical company Pfizer
PFE,
-0.99%
,
Or made by biotechnology moderna
MRNA,
-1.44%
,
From “sufficient attention” Independent The newspaper quoted government sources.

People in their thirties can be vaccinated against AstraZeneca even if vaccination is significantly delayed by waiting for an alternative. Times The newspaper reported.

is more than 34 million According to the latest government statistics, people in the UK are vaccinated with at least one COVID-19 vaccine, 15 million are vaccinated with both, and the government will eventually provide the vaccine to all adults. It states that it will. Of July.

read: EU and UK regulators say the AstraZeneca vaccine is safe, but British people under the age of 30 will be offered alternative shots

In April, the UK Medicines and Healthcare Products Regulatory Authority (MHRA) emphasized that profits outweigh risks. “Overwhelming majority” Recommended for people and for vaccines without age restrictions. However, it is more “balanced” for young people, and JCVI urged adults under the age of 30 to recommend alternatives to the AstraZeneca vaccine when possible.

The European Medicines Agency says that the risk of COVID-19 is Exceed Especially those of blood clots in the elderly.

Denmark has permanently stopped using the AstraZeneca vaccine Following the possibility of association with very rare cases of blood clots, while some other European countries have restricted the use of the vaccine to the elderly.Denmark too Exclusion COVID-19 Shots Made by Healthcare Companies Johnson & Johnson
JNJ,
+ 0.40%

From that vaccination program, through a potential link to a rare but serious form of blood clot.

On Thursday, MHRA Some evidence Rare blood clots associated with the AstraZeneca vaccine occurred more often in women than in men, but warned that the difference in incidence was small. “Currently, there is some evidence that women have higher reported incidences than men, but this is not seen in all age groups and the difference remains small,” MHRA said. Mentioned in a weekly update on coagulation issues.

read: According to Moderna, the COVID-19 vaccine has a 96% efficacy rate for teens who receive a single dose.

The latest weekly figures from MHRA show that the incidence of rare blood clots and low platelet levels was 10.5 per million, compared to 9.3 per million last week. ..

According to the MHRA, the incidence of rare blood clots and low platelet levels was 10.5 per million, compared to 9.3 per million last week. There were 242 thrombi, and 6 occurred after the second dose. By April 28, there were 22.6 million first doses of AstraZeneca vaccine in the UK and 5.9 million second doses.

“There remains advice that the benefits of vaccines outweigh the risks of the majority of people,” said MHRA.

COVID-19 vaccine to replace AstraZeneca in the UK under 40: Report

http://www.marketwatch.com/news/story.asp?guid=%7B49AA4BE0-F11F-423E-A455-0F368FDAEE78%7D&siteid=rss&rss=1 COVID-19 vaccine to replace AstraZeneca in the UK under 40: Report

Back to top button